[Alpha-glucosidase inhibitors: a new therapeutic approach in diabetes and functional hypoglycemia].
Acarbose, a potent alpha-glucosidase inhibitor, represents a new concept for the treatment of metabolic disorders, and particularly diabetes mellitus. It slows the absorption kinetics of dietary carbohydrates by reversible competitive inhibition of alpha-glucosidase activity, and so reduces the post-prandial blood glucose increment and insulin response. For these reasons, the drug has been successfully used not only in the treatment of type I or type II diabetes, but also in the management of reactive hypoglycemias and dumping syndrome. In addition, some data suggest a possible role in the treatment of type IV hyperlipidemia. Because of the delay in absorption of oligo- and disaccharides resulting from its administration, a colic bacterial fermentation occurs, accounting for the frequent abdominal discomfort mentioned by the patients. These side effects would be lessened with the second generation glucosidase inhibitors now in progress.
Brogard
J M
JM
Département de médecine interne, Clinique médicale B, CHU, Strasbourg.
Willemin
B
B
Blicklé
J F
JF
Lamalle
A M
AM
Stahl
A
A
D020909:Acarbose; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy*; D014312:Trisaccharides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D065089:Glycoside Hydrolase Inhibitors; D014312:Trisaccharides; D020909:Acarbose
Inhibiteurs des alpha-glucosidases: une nouvelle approche thérapeutique du diabète et des hypoglycémies fonctionnelles.